Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orchestra BioMed Holdings (OBIO) Depreciation and Depletion (2022 - 2024)

Historic Depreciation and Depletion for Orchestra BioMed Holdings (OBIO) over the last 3 years, with Q3 2024 value amounting to $76000.0.

  • Orchestra BioMed Holdings' Depreciation and Depletion rose 704.23% to $76000.0 in Q3 2024 from the same period last year, while for Sep 2024 it was $296000.0, marking a year-over-year increase of 422.54%. This contributed to the annual value of $287000.0 for FY2023, which is 2927.93% up from last year.
  • Latest data reveals that Orchestra BioMed Holdings reported Depreciation and Depletion of $76000.0 as of Q3 2024, which was up 704.23% from $74000.0 recorded in Q2 2024.
  • Orchestra BioMed Holdings' 5-year Depreciation and Depletion high stood at $76000.0 for Q3 2024, and its period low was $48000.0 during Q1 2022.
  • Its 3-year average for Depreciation and Depletion is $66454.5, with a median of $71000.0 in 2023.
  • Its Depreciation and Depletion has fluctuated over the past 5 years, first soared by 4791.67% in 2023, then soared by 277.78% in 2024.
  • Over the past 3 years, Orchestra BioMed Holdings' Depreciation and Depletion (Quarter) stood at $70000.0 in 2022, then rose by 2.86% to $72000.0 in 2023, then increased by 5.56% to $76000.0 in 2024.
  • Its Depreciation and Depletion was $76000.0 in Q3 2024, compared to $74000.0 in Q2 2024 and $74000.0 in Q1 2024.